Policy & Regulation
Emerald Clinical Trials honoured with 2026 Asia Pacific Biopharma Excellence Award
13 March 2026 - Emerald Clinical Trials, a global clinical research organisation (CRO), announced on Thursday that it has received the Best Clinical Trials Supplier Award: Outstanding Patient Recruitm...
Inimmune reports dosing of first patient in Phase 2 allergen challenge chamber trial of INI-2004
13 March 2026 - Clinical-stage biotechnology company Inimmune Corporation announced on Thursday the completion of enrolment and dosing of the first patient in its Phase 2 allergen challenge chamber tr...
WuXi Biologics wins at 2026 Asia-Pacific Biopharma Excellence Awards for leadership in bioprocessing, manufacturing excellence, and digital innovation
13 March 2026 - WuXi Biologics ('WuXi Bio') (HK:2269), a global Contract Research, Development and Manufacturing Organization (CRDMO), announced on Thursday that it has received six prestigi...
Precision for Medicine opens new Japan office
12 March 2026 - Precision for Medicine, a biomarker-driven clinical research and development services organisation, announced on Wednesday the opening of its new office in Japan.The new Tokyo office s...
Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial
12 March 2026 - Swedish clinical-stage pharmaceutical company Gesynta Pharma AB announced on Wednesday that the first patient has been dosed in its its Phase 2 clinical proof-of-concept trial of vipog...
Avene partners with BotDesign to advance clinical studies in dermo-cosmetics
12 March 2026 - Avene, a brand of French pharmaceutical and cosmetics company Pierre Fabre Laboratories, announced on Wednesday a breakthrough in the field of clinical studies in dermo-cosmetics in pa...